16 December 2015 - Merck announced today that the U.S. FDA approved an expanded age indication for Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), Merck’s 9-valent HPV vaccine, to now include use in males 16 through 26 years of age, for the prevention of anal cancer caused by HPV types 16, 18, 31, 33, 45, 52 and 58, precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and genital warts caused by HPV types 6 and 11.

For more details, go to: http://www.mercknewsroom.com/news-release/vaccine-news/fda-approves-expanded-age-indication-gardasil-9-males